Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 ...
Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...
On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...
A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...
Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma ...
Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...
BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...
Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and ...
Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The ...
TOPLINE: Sjögren disease (SjD) presents three distinct phenotypes ― B-cell active with low symptom burden, high systemic ...
Two charity quiz nights are set to be held at a Pickering farm shop and café. The Cedarbarn Farm Shop and Café, which raised more than £40,000 for Macmillan Cancer Support last year, has announced two ...